Anne-Laure Gagez

Anne-Laure Gagez

Auto-generated profile, based on publicly available information

Anne-Laure Gagez

CNRS UMR 5235, Université de Montpellier, Montpellier, France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2014 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
CJCamille Juin
Camille Juin
JCJean-René Chérouvrier
Jean-René Chérouvrier
TVThiery Valerie
Thiery Valerie
AGAnne-Laure Gagez
Anne-Laure Gagez
JBJean-Baptiste Bérard
Jean-Baptiste Bérard
Laurent PicotLaurent Picot
Laurent Picot

1 November 2013 in Marine Drugs
Verified
Journal Article
Open access
PDF file
PBPaul-Hubert Baudelet
Paul-Hubert Baudelet
AGAnne-Laure Gagez
Anne-Laure Gagez
JBJean-Baptiste Bérard
Jean-Baptiste Bérard
CJCamille Juin
Camille Juin
NBNicolas Bridiau
Nicolas Bridiau
Laurent PicotLaurent Picot
Laurent Picot
The glaucophyte Cyanophora paradoxa (Cp) was chemically investigated to identify pigments efficiently inhibiting malignant melanoma, mammary carcinoma and lung adenocarcinoma cells growth. Cp water and ethanol extracts significantly inhibited the growth of the three cancer cell lines in vitro, at 100 µg·mL−1. Flash chromatography of the Cp ethanol extract, devoid of c-phycocyanin and allophycocyanin, enabled the collection of eight fractions, four of which strongly inhibited cancer cells growth at 100 µg·mL−1. Particularly, two fractions inhibited more than 90% of the melanoma cells growth, one inducing apoptosis in the three cancer cells lines. The detailed analysis of Cp pigment composition resulted in the discrimination of 17 molecules, ten of which were unequivocally identified by high resolution mass spectrometry. Pheophorbide a, β-cryptoxanthin and zeaxanthin were the three main pigments or derivatives responsible for the strong cytotoxicity of Cp fractions in cancer cells. These data point to Cyanophora paradoxa as a new microalgal source to purify potent anticancer pigments, and demonstrate for the first time the strong antiproliferative activity of zeaxanthin and β-cryptoxanthin in melanoma cells.

22 January 2015 in Archives of Microbiology
Verified
Journal Article
Closed access
PDF file
FTFatoumata Tambadou
Fatoumata Tambadou
TCThibault Caradec
Thibault Caradec
AGAnne-Laure Gagez
Anne-Laure Gagez
ABAntoine Bonnet
Antoine Bonnet
VSValérie Sopéna
Valérie Sopéna
RCromain chevrot
romain chevrot

1 September 2014 in Current Opinion in Oncology
Verified
Journal Article
Closed access
AGAnne-Laure Gagez
Anne-Laure Gagez
GCGuillaume Cartron
Guillaume Cartron
Obinutuzumab is a new anti-CD20 monoclonal antibody which demonstrated clinical superiority compared with rituximab in a recent phase III study. There is a need to better understand how this antibody differs from rituximab and why it could modify the landscape of the treatment of CD20 malignancies in the near future. Antibody-dependent cellular cytotoxicity plays a critical role in clinical activity of rituximab. To increase antibody-dependent cellular cytotoxicity, a strategy improving the affinity between the Fc portion of the antibody and FcγRIIIa expressed by effector cells has been recently developed. This strategy modifies the carbohydrate located between the two Fc arms. Thus, the lack of fucose on IgG oligosaccharide improves binding to FcγRIII and antibody-dependent cellular cytotoxicity. Obinutuzumab recognized a CD20 epitope different from that bound by rituximab. This property confers different features to obinutuzumab mechanisms of action with a noncaspase-dependent direct-cell death and the lack of complement-dependent cytotoxicity. Obinutuzumab demonstrated significant activity in animal models, and phase I or II studies showed clinical activity in different subtypes of CD20 diseases. Obinutuzumab, a type II glycoengineered monoclonal antibody, is characterized by an increased antibody-dependent cellular cytotoxicity and direct-cell death but no complement-dependent cytotoxicity. Recent clinical data demonstrated a superiority of obinutuzumab compared with rituximab, suggesting that this antibody should be, in the future, the backbone of the treatment of B-lymphoproliferative disorders.

1 November 2013 in Tetrahedron
Verified
Journal Article
Open access
NMNada Marquise
Nada Marquise
PHPhilip J. Harford
Philip J. Harford
FCFloris Chevallier
Floris Chevallier
TRThierry Roisnel
Thierry Roisnel
VDVincent Dorcet
Vincent Dorcet
FMFlorence Mongin
Florence Mongin

25 October 2016 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
MTMira Tout
Mira Tout
AGAnne-Laure Gagez
Anne-Laure Gagez
SLStéphane Leprêtre
Stéphane Leprêtre
VGValérie Gouilleux-Gruart
Valérie Gouilleux-Gruart
NANicolas Azzopardi
Nicolas Azzopardi
DTDavid Ternant
David Ternant